MBP8298: Phase II ongoing

For a third time, a DSMB recommended continuation of the double-blind, European Phase II MINDSET-01 trial comparing 50 mg of IV MBP8298 vs. placebo in 218 patients. Late last year, Eli Lilly licensed ...